open access

Vol 25, No 4 (2020)
Original research articles
Published online: 2020-07-01
Submitted: 2019-11-18
Get Citation

Long-term outcome comparison for standard fractionation (59 Gy) versus hyperfractionated (45 Gy) radiotherapy plus concurrent chemotherapy for limited-stage small-cell lung cancer

John M. Watkins, J. Kyle Russo, Nicholas Andresen, Coyt R. Rountree, Amir Zahra, Sarah L. Mott, Daniel J. Herr, Jacy O’Keefe, Bryan G. Allen, Anand K. Sharma, John M. Buatti
DOI: 10.1016/j.rpor.2020.03.017
·
Rep Pract Oncol Radiother 2020;25(4):489-493.

open access

Vol 25, No 4 (2020)
Original research articles
Published online: 2020-07-01
Submitted: 2019-11-18

Abstract

Background

Concurrent chemoradiotherapy (CCRT) is commonly employed in limited-stage small-cell lung cancer (LS-SCLC); however, the optimal radiotherapy regimen is still unknown. This 3-institution analysis compares long-term disease control and survival outcomes for once- (QD) versus twice-daily (BID) radiotherapy at contemporary doses.

Methods and Materials

Data were collected for LS-SCLC patients treated with platinum-based CCRT and planned RT doses of >5940 cGy at >180 cGy QD or >4500 cGy at 150 cGy BID. Comparative outcome analyses were performed for treatment groups.

Results

From 2005 through 2014, 132 patients met inclusion criteria for analysis (80 QD, 52 BID). Treatment groups were well-balanced, excepting higher rate of advanced mediastinal staging, longer interval from biopsy to treatment initiation, and lower rate of prophylactic cranial irradiation for the QD group, as well as institutional practice variation. At median survivor follow-up of 33.5 months (range, 4.6–105.8), 80 patients experienced disease failure (44 QD, 36 BID), and 106 died (62 QD, 44 BID). No differences in disease control or survival were demonstrated between treatment groups.

Conclusion

The present analysis did not detect a difference in disease control or survival outcomes for contemporary dose QD versus BID CCRT in LS-SCLC.

Abstract

Background

Concurrent chemoradiotherapy (CCRT) is commonly employed in limited-stage small-cell lung cancer (LS-SCLC); however, the optimal radiotherapy regimen is still unknown. This 3-institution analysis compares long-term disease control and survival outcomes for once- (QD) versus twice-daily (BID) radiotherapy at contemporary doses.

Methods and Materials

Data were collected for LS-SCLC patients treated with platinum-based CCRT and planned RT doses of >5940 cGy at >180 cGy QD or >4500 cGy at 150 cGy BID. Comparative outcome analyses were performed for treatment groups.

Results

From 2005 through 2014, 132 patients met inclusion criteria for analysis (80 QD, 52 BID). Treatment groups were well-balanced, excepting higher rate of advanced mediastinal staging, longer interval from biopsy to treatment initiation, and lower rate of prophylactic cranial irradiation for the QD group, as well as institutional practice variation. At median survivor follow-up of 33.5 months (range, 4.6–105.8), 80 patients experienced disease failure (44 QD, 36 BID), and 106 died (62 QD, 44 BID). No differences in disease control or survival were demonstrated between treatment groups.

Conclusion

The present analysis did not detect a difference in disease control or survival outcomes for contemporary dose QD versus BID CCRT in LS-SCLC.

Get Citation

Keywords

Hyperfractionation; Small-Cell carcinoma; Lung neoplasms; Combined-Modality therapy; Radiotherapy.

About this article
Title

Long-term outcome comparison for standard fractionation (59 Gy) versus hyperfractionated (45 Gy) radiotherapy plus concurrent chemotherapy for limited-stage small-cell lung cancer

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 25, No 4 (2020)

Pages

489-493

Published online

2020-07-01

DOI

10.1016/j.rpor.2020.03.017

Bibliographic record

Rep Pract Oncol Radiother 2020;25(4):489-493.

Keywords

Hyperfractionation
Small-Cell carcinoma
Lung neoplasms
Combined-Modality therapy
Radiotherapy.

Authors

John M. Watkins
J. Kyle Russo
Nicholas Andresen
Coyt R. Rountree
Amir Zahra
Sarah L. Mott
Daniel J. Herr
Jacy O’Keefe
Bryan G. Allen
Anand K. Sharma
John M. Buatti

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl